Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron, Sanofi launch new immuno-oncology collaboration
As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing and plan to initiate
As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing and plan to initiate
The food & beverage market offers a broad variety of filtration solutions for sterile air, steam or liquid. Selecting the right system has a significant influence on operational
Narcan Nasal Spray has been granted Fast Track Designation by the FDA. Within 60 days of the submission date, the FDA will determine whether it will accept the
Fresenius Kabi Glucagon for Injection is indicated for use as a diagnostic aid during radiologic examinations and is available in 10-packs of 1mg vials. "Glucagon for Injection is
Unlike traditional insulin injections, Insulin PharmFilm, the proprietary nanoformulated transbuccal insulin film product delivers insulin through the use of a rapidly dissolving mucoadhesive film that is placed on
Invion and Hovione will collaborate to develop the proprietary novel technology — a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler. Under the terms
Medytox, the Botulinum Toxin brand, occupies the highest market share in Korea, and is also the fourth company in the world successfully developed and produced Botulinum Toxin, leveraging
The recalled lots are as follows:Lot # Exp. Date Vial Size NDC# individual vials NDC# carton of 5 vials31317857B 8/2015 100 mL 0703-3019-11 0703-3019-1231317859B 12/2015 100 mL 0703-3019-11
"The expanded indication of Kyprolis provides patients with relapsed multiple myeloma a new therapeutic option, helping to address a real unmet need for this common blood cancer," said
Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response. The FDA’s Office of